Riordan, Lewis & Haden has acquired DCRX Infusion, a provider of nutritional therapy to patients with end stage renal disease. The firm partnered with Robert Funari, a healthcare executive with a background in building specialty pharmaceutical companies, on this transaction. Skyline Global Partners also participated in the DCRX Infusion investment.
DCRX Infusion is a provider of nutritional therapy to patients with end stage renal disease. DCRX assists dialysis patients who are at higher risk of adverse clinical outcomes because of chronic malnutrition. The company’s clinicians work with referring nephrologists to formulate and deliver the appropriate parenteral nutrition therapy for each patient. DCRX also provides a team of pharmacists, nurses, and dieticians that offer comprehensive clinical consulting support for dialysis centers and their patients. The company is based in Sunrise, FL (www.dcrxinfusion.com).
Prior to partnering with Riordan, Lewis & Haden on the acquisition of DCRX Infusion, Mr. Funari was CEO of Crescent Healthcare and of Syncor International. “I look forward to working with the excellent DCRX team. Their passion to help dialysis patients, combined with the strategic insight that Riordan, Lewis & Haden brings from its 30 year history of helping build high performance service enterprises, are the building blocks which excite me about this outstanding growth opportunity,” said Mr. Funari.
Riordan, Lewis & Haden invests in high growth, lower middle market, enterprises. Sectors of interest include business services, healthcare, and government services. The firm currently manages over $600 million of assets and is actively seeking new portfolio companies. Riordan, Lewis & Haden is based in Los Angeles, CA (www.rlhequity.com).
“In today’s rapidly changing healthcare environment, DCRX is well positioned to continue to achieve significant growth because the company provides cost-effective clinical care and outstanding service. With the benefit of Bob Funari’s leadership and expertise, DCRX will accelerate its success and improve the quality of life for more dialysis patients,” said Michel Glouchevitch, a partner at Riordan Lewis & Haden.
Skyline Global Partners invests from $10 million to $30 million in equity in lower middle market companies that have revenue of $20 million to $100 million and EBITDA of $3 million to $15 million. Sectors of interest include healthcare, manufacturing, and business services. The firm is based in Chicago, IL (www.skylinegp.com).
